Evolution until death of two members of a family with A3243G mutation and MELAS phenotype versus diabetes mellitus;Evolución hasta el fallecimiento de dos miembros de una familia con la mutación A3243G y fenotipo MELAS frente a diabetes mellitus

Neurologia

Volumn 21, Issue 6, 2006, Pages 327-332

  Pérez López Fraile, M Isabel ^a   Barrena, R ^a   Montoya, J ^b   Marta, E ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

A3243G mutation; Cause of death; Diabetes mellitus; Epilepsy; MELAS

Indexed keywords

IDEBENONE; TRANSFER RNA; VALPROIC ACID;

A3243G GENE; ACUTE KIDNEY FAILURE; ADULT; ANAMNESIS; ARTICLE; BRAIN ISCHEMIA; BRONCHOPNEUMONIA; CASE REPORT; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DEATH; DEMENTIA; DIABETES MELLITUS; DISEASE COURSE; EVOLUTION; FAMILY; FEMALE; GENE MUTATION; HEARING IMPAIRMENT; HUMAN; MALE; MELAS SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHENOTYPE; RNA GENE; SEIZURE; SEPTIC SHOCK; STROKE; SYMPATHECTOMY; VASCULAR DISEASE;

ADULT; BRAIN; DEAFNESS; DIABETES MELLITUS; FATAL OUTCOME; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MELAS SYNDROME; MIDDLE AGED; PEDIGREE; PHENOTYPE; POINT MUTATION; RNA, TRANSFER, LEU;

EID: 33746427026     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Leu(UUR) mutation causes aminoacylation deficiency and concomitant reduced association of mRNA with ribosomes. J Biol Chem 2000;275:19198-209.
2. Torroni A, Campos Y, Rengo C, Sellitto D, Achilli A, Magri C, et al. Mitochondrial DNA haplogroups do not play a role in the variable phenotypic presentation of the A3243G mutation. Am J Hum Genet 2003;72:1005-12.
3. Leu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 1990;348:651-53.
4. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke like episodes. Ann Neurol 1984;16:481-8.
5. Van Den Ouweland JMW, Lemkes HHPJ, Gerbitz KD, Maassen JA. Maternally inherited diabetes and deafness (MIDD): a distinct subtype of diabetes associated with a mitochondrial tRNA Leu (UUR) gene point mutation. Musc Nerv 1995(Suppl. 3)5124-30.
6. Deschauer M, Muller T, Wieser T, Schulte-Mattler W, Kornhuber M, Zierz S. Hearing impairment is common in various phenotypes of the mitochondrial DNA A3243G mutation. Arch Neurol 2001;58:1885-8.
7. Leu(UUR) mutation at base pair 3243 of the mitochondrial DNA. Neurology 1995;45:1188-92.
8. Goto Y. Clinical features of MELAS and mitochondrial DNA mutations. Musc Nerv 1995(Suppl. 3):S107-12.
9. Huang CC, Chen RS, Chu NS, Pang CY, Wei YH. Random mitotic segregation of mitochondrial DNA in MELAS syndrome. Acta Neurol Scand 1996;93:198-202.
10. Leu(UUR) mutation of mitochondrial DNA. Acta Neurol Scand 1995;91:62-5.
11. Leu(UUR) A3243G. Ann Neurol 2000;47:179-85.
12. Ikejiri Y, Mori E, Ishii K, Nishimoto K, Yasuda M, Sasaki M. Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 1996;47:583-5.
13. Oguro H, Iijima K, Takahashi K, Nagai A, Bokura H, Yamaguchi S, et al. Successful treatment with succinate in a patient with MELAS. Intern Med 2004;43:427-31.
14. Goto Y, Horai S, Matsuoka T, Koga Y, Nihei K, Kobayashi M, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology 1992;42:545-50.
15. Suzuki T, Koizumi J, Shiraishi H, Ishikawa N, Ofuku K, Sasaki M, et al. Mitochondrial encephalomyopathy (MELAS) with mental disorder. CT, MRI and SPECT findings. Neuroradiology 1990;32:74-6.
16. Sharfstein SR, Gordon MF, Libman RB, Malkin ES. Adult-onset MELAS presenting as herpes encephalitis. Arch Neurol 1999;56:241-3.
17. Sartor H, Loose R, Tucha O, Klein HE, Lange KW. MELAS: a neuropsychological and radiological follow-up study. Acta Neurol Scand 2002;106:309-13.
18. Iizuka T, Sakai F, Kan S, Suzuki N. Slowly progressive spread of the stroke-like lesions in MELAS. Neurology 2003;61:1238-44.
19. Iizuka T, Sakai F, Suzuki N, Hata T, Tsukahara S, Fukuda M, et al. Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome. Neurology 2002;59:816-24.
20. Canafoglia L, Franceschetti S, Antozzi C, Carrara F, Farina L, Granata T, et al. Epileptic phenotypes associated with mitochondrial disorders. Neurology 2001;56:1340-6.
21. Durand-Dubief F, Ryvlin P, Mauguière F. Polymorphisme de l'épilepsie associée à la mutation A3243G de l'ADN mitochondrial (MELAS): la raison d'un diagnostic tardif. Rev Neurol (Paris) 2004;160:824-9.
22. Lam CW, Lau CH, Williams JC, Chan YW, Wong LJC. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 1997;156:562-4.
23. Chou Y, Chen W, Yang C. Valproate therapy aggravates seizures in the MELAS: report of a case. Abstract Acta Neurol Taiwan 1998;7:202-8.
24. Feddersen B, Bender A, Arnold S, Klopstock T, Noachtar S. Aggressive confusional state as a clinical manifestation of status epilepticus in MELAS. Neurology 2003;61:1149-50.
25. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998;39:5-17.
26. Hirsch E, Genton P. Antiepileptic drug-induced pharmacodynamic aggravation of seizures: does valproate have a lower potential? CNS Drugs 2003;17:633-40.
27. Campistol J, Chávez B, Vilaseca MA, Artuch R. Antiepileptic drugs and carnitine. Rev Neurol 2000;30(Suppl. 1):S105-9.
28. Frackowiak RSJ, Herold S, Petty RKH, Morgan-Hughes JA. The cerebral metabolism of glucose and oxygen-measured with positron tomography in patients with mitochondrial diseases. Brain 1988;111:1009-24.
29. Molnár MJ, Valikovics A, Molnár S, Tron L, Diószeghy P, Mechler F, et al. Cerebral blood flow and glucose metabolism in mitochondrial disorders. Neurology 2000;55:544-8.
30. Napolitano A, Salvetti S, Vista M, Lombardi V, Siciliano G, Giraldi C. Long-term treatment with idebenone and riboflavin in a patient with MELAS. Neurol Sci 2000;21(Suppl. 5):981-2.
31. Artuch R, Aracil A, Mas A, Monros E, Vilaseca MA, Pineda M. Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients. Neuropediatrics 2004;35:95-8.
32. Cock H, Schapira AHV. Mitochondrial DNA mutations and mitochondrial dysfunction in epilepsy. Epilepsia 1999;40(Suppl. 3):S33-40.
33. Klopstock T, Jaksch M, Gasser T. Age and cause of death in mitochondrial diseases. Neurology 1999;11:53:855-7.
34. Arpa J, Cruz-Martínez A, Campos Y, Gutiérrez-Molina M, Garcia-Río F, Pérez-Conde C, et al Prevalence and progression of mitochondrial diseases: a study of 50 patients. Muscle Nerve 2003;28:690-5.
35. Suzuki S. Diabetes mellitus with mitochondrial gene mutations in Japan. Ann N Y Acad Sci 2004;1011:185-92.
36. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004;164:1422-6.
37. Kaufmann P, Shungu DC, Sano MC, Jhung S, Engelstad K, Mitsis E, et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004;62:1297-302.
38. Paljarvi L. Brain lactic acidosis and ischemic cell damage: a topographic study with high-resolution light microscopy of early recovery in a rat model of severe incomplete ischemia. Acta Neuropathol 1984;64:89-98.